ACUITY: Bivalirudin vs. Heparin or Enoxaparin in Treatment of Patients with Non-STEMI
Study of:
Bivalirudin is an FDA-approved product for management of patients with new onset, unstable angina undergoing angioplasty. This study involves a randomized comparison of bivalirudin (Angiomax) versus enoxaparin (Lovenox) or Heparin in patients undergoing an angiogram for Acute Coronary Syndrome.
The goal is to establish optimal anti-thrombotic treatment regiments in patients wiht unstable angina/non-ST-segment elevation myocardial infarction (non-STEMI). Study participants are men and non-pregnant women 18 years of age and older who have symptoms and signs of moderate- or high-risk unstable angina/non-STEMI. Study participants receive drugs prior to, during and following angiogram by IV according to usual treatment. Study follow-up continues during hospital stay and then by a 30-day follow-up telephone call.
Jay H. Traverse, MD, FACC, FAHA
Theresa Happ, RN
Gretchen Peichel, RN
Talia Pierce, RN
For more information about this study or the Acute Coronary Syndromes Research program at the Minneapolis Heart Institute Foundation, please call Carol Stone at 612-863-9124.
|